Cagrilintide is an investigational long-acting amylin analog studied for its role in appetite regulation, satiety signaling, and metabolic control. It is structurally designed to mimic the activity of amylin, a hormone co-secreted with insulin.
Cagrilintide is not an approved medication and remains a research-only compound.
Cagrilintide acts on amylin receptors located in the:
Central nervous system (particularly appetite centers in the brain)
Gastrointestinal signaling pathways
Through these receptors, it influences:
Satiety signaling (feeling full)
Meal size regulation
Gastric emptying rate
Central appetite control pathways
Its long-acting design allows for sustained receptor engagement, making it useful in research models examining prolonged appetite modulation.
Enhances feelings of fullness in preclinical studies
Reduces drive to initiate or continue feeding behavior
Acts directly on brain pathways involved in appetite control
Complements incretin-based signaling without overlapping mechanisms
Engineered for extended half-life compared to native amylin
Supports steady signaling rather than rapid peaks and troughs
Works alongside insulin- and GLP-1–related pathways in research models
Studied for its ability to reduce compensatory hunger responses
